New Classifications of Five Distinct “Sleep” Profi... ...
Science in the Age of AI | AI for Science Forum...
Ask the Heart Doctor | Heart Valve Disease and Sur...
High-speed imaging tracks live brain cell activity...
NAD⁺ restores memory in Alzheimer's disease models...
Mark Cuban: A Master Disrupter for American Health...
Teen girls facing the most adversity showed the biggest gain...
September 15,2026
Specialized imaging reveals hormone-driven brain changes...
September 14,2026
Submillimeter MRI reveals brain hubs that guide risky decisi...
September 12,2026
Risk of herpes zoster among breast cancer survivors in Japan...
September 11,2026
Three proteins help organs tailor shared circadian clock to ...
September 10,2026
Should you worry about melatonin and heart failure? The evid...
December 02,2025
Category
Traditional Medicine
Q & A
Wellness
Drug Discovery
Technology & AI
Clinical Pearl Series
Breakthroughs
Immunology & Rheumatology
Reproduction
Hepatobiliary&Pancreas Surgery
Most Read
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Today's News
GOSH BRC Showcase 2025 - Genomic medicine...
Can a twice-a-year shot help end the HIV...
Announcement of the 2025 Nobel Prize in ...
Reprogramming Stem Cells Could Cure Type...
Why MDMA did NOT get FDA approval...
More News
Rituximab Maintenance Effective for Autoimmune Cytopenias

Rituximab Maintenance Effective for Autoimmune Cytopenias

August 2023Thomas R. CollinsPatients with autoimmune cytopenias had longer durations of response after induction treatment with rituximab when rituximab was continued as maintenance therapy compared w
Oncology February 18,2024
Rituximab Maintenance Effective for Autoimmune Cytopenias

Rituximab Maintenance Effective for Autoimmune Cytopenias

August 2023Thomas R. CollinsPatients with autoimmune cytopenias had longer durations of response after induction treatment with rituximab when rituximab was continued as maintenance therapy compared w
Oncology February 18,2024
Bloomberg School Researchers Develop Universal Risk Predictor for Cardiovascular Disease

Bloomberg School Researchers Develop Universal Risk Predictor for Cardiovascular Disease

Universal risk predictor for cardiovascular disease, suitable for use in both primary and secondary prevention, would streamline risk assessmentPublishedJanuary 29, 2024EPIDEMIOLOGYResearchers from th
Oncology February 18,2024
Bloomberg School Researchers Develop Universal Risk Predictor for Cardiovascular Disease

Bloomberg School Researchers Develop Universal Risk Predictor for Cardiovascular Disease

Universal risk predictor for cardiovascular disease, suitable for use in both primary and secondary prevention, would streamline risk assessmentPublishedJanuary 29, 2024EPIDEMIOLOGYResearchers from th
Oncology February 18,2024
Anti-PF4 Immunothrombosis Absent Proximate Heparin or Adenovirus Vector Vaccine Exposure

Anti-PF4 Immunothrombosis Absent Proximate Heparin or Adenovirus Vector Vaccine Exposure

February 2024Lara C. Pullen, PhDNew research reveals that patients with thrombocytopenia, thrombosis, and very high D-dimer levels could have platelet-activating vaccine-induced immune thrombocytopeni
Oncology February 18,2024
Anti-PF4 Immunothrombosis Absent Proximate Heparin or Adenovirus Vector Vaccine Exposure

Anti-PF4 Immunothrombosis Absent Proximate Heparin or Adenovirus Vector Vaccine Exposure

February 2024Lara C. Pullen, PhDNew research reveals that patients with thrombocytopenia, thrombosis, and very high D-dimer levels could have platelet-activating vaccine-induced immune thrombocytopeni
Oncology February 18,2024
New study flips the script on liver cancer

New study flips the script on liver cancer

by University of California - San DiegoUC San Diego scientists find the protein ATF4 prevents liver damage and its progression to cancer by blocking ferroptosis, an iron-dependent form of liver c
Oncology February 18,2024
New study flips the script on liver cancer

New study flips the script on liver cancer

by University of California - San DiegoUC San Diego scientists find the protein ATF4 prevents liver damage and its progression to cancer by blocking ferroptosis, an iron-dependent form of liver c
Oncology February 18,2024
Survival in Primary Hemophagocytic Lymphohistiocytosis Can Be as High as 100%

Survival in Primary Hemophagocytic Lymphohistiocytosis Can Be as High as 100%

February 2024Lara C. Pullen, PhDResults from a contemporary standard-of-care study of patients with primary hemophagocytic lymphohistiocytosis (pHLH) reveal that firstline etoposide-based therapy is m
Oncology February 18,2024
Survival in Primary Hemophagocytic Lymphohistiocytosis Can Be as High as 100%

Survival in Primary Hemophagocytic Lymphohistiocytosis Can Be as High as 100%

February 2024Lara C. Pullen, PhDResults from a contemporary standard-of-care study of patients with primary hemophagocytic lymphohistiocytosis (pHLH) reveal that firstline etoposide-based therapy is m
Oncology February 18,2024
Researchers gain structural insights into the immune modulator Siglec-15 and its interaction with T cells

Researchers gain structural insights into the immune modulator Siglec-15 and its interaction with T cells

by CIC bioGUNEa Cartoon and surface representation of two views of the crystal structure of Siglec-15 in complex with anti-Siglec-15 5G12 Fab. 5G12 is composed of a heavy chain (HC) (in orange) and a
Oncology February 18,2024
Researchers gain structural insights into the immune modulator Siglec-15 and its interaction with T cells

Researchers gain structural insights into the immune modulator Siglec-15 and its interaction with T cells

by CIC bioGUNEa Cartoon and surface representation of two views of the crystal structure of Siglec-15 in complex with anti-Siglec-15 5G12 Fab. 5G12 is composed of a heavy chain (HC) (in orange) and a
Oncology February 18,2024
Small-Volume Blood Collection Tubes Can Reduce Transfusions in Intensive Care

Small-Volume Blood Collection Tubes Can Reduce Transfusions in Intensive Care

January 2024Leah LawrenceNew data indicate that the use of tubes that automatically collect less blood in the intensive care unit (ICU) may decrease red blood cell (RBC) transfusions without affecting
Oncology February 18,2024
Small-Volume Blood Collection Tubes Can Reduce Transfusions in Intensive Care

Small-Volume Blood Collection Tubes Can Reduce Transfusions in Intensive Care

January 2024Leah LawrenceNew data indicate that the use of tubes that automatically collect less blood in the intensive care unit (ICU) may decrease red blood cell (RBC) transfusions without affecting
Oncology February 18,2024
Health Disparities Persist in Hemophilia Life Expectancy

Health Disparities Persist in Hemophilia Life Expectancy

January 2024Lara C. Pullen, PhDBetween 1999 and 2020, recorded hemophilia death (rHD) rates in the U.S. improved in males across all racial and ethnic groups.Stacey A. Fedewa, PhD, MPH,of
Oncology February 18,2024
Health Disparities Persist in Hemophilia Life Expectancy

Health Disparities Persist in Hemophilia Life Expectancy

January 2024Lara C. Pullen, PhDBetween 1999 and 2020, recorded hemophilia death (rHD) rates in the U.S. improved in males across all racial and ethnic groups.Stacey A. Fedewa, PhD, MPH,of
Oncology February 18,2024
Blood, Marrow Transplant Recipients at Increased Risk for Coronary Heart Disease

Blood, Marrow Transplant Recipients at Increased Risk for Coronary Heart Disease

November 2023Lara C. Pullen, PhDA new study reports on the long-term risk for coronary heart disease (CHD) in blood or marrow transplant (BMT) recipients and identifies individuals who are at high ris
Oncology February 18,2024
Blood, Marrow Transplant Recipients at Increased Risk for Coronary Heart Disease

Blood, Marrow Transplant Recipients at Increased Risk for Coronary Heart Disease

November 2023Lara C. Pullen, PhDA new study reports on the long-term risk for coronary heart disease (CHD) in blood or marrow transplant (BMT) recipients and identifies individuals who are at high ris
Oncology February 18,2024
Study finds TNF blockers are not associated with poor pregnancy outcomes

Study finds TNF blockers are not associated with poor pregnancy outcomes

byAmerican College of RheumatologyCredit: Pixabay/CC0 Public DomainAccording tonew researchatACR Convergence 2023, the American College of Rheumatology's (ACR) annual meeti
Immunology & Rheumatology February 18,2024
Study finds TNF blockers are not associated with poor pregnancy outcomes

Study finds TNF blockers are not associated with poor pregnancy outcomes

byAmerican College of RheumatologyCredit: Pixabay/CC0 Public DomainAccording tonew researchatACR Convergence 2023, the American College of Rheumatology's (ACR) annual meeti
Immunology & Rheumatology February 18,2024
More News
Week’s Top
Podcasts
... Health spending has been rising across rich countries with different systems ... ... GOSH BRC Showcase 2025 - Genomic medicine ... ... At what age do people experience depression for the first time? Depression can affect people over long periods of their lives. Some people experience this condition continuously, while for others, it occu...
FIND US ON
ABOUT
Who We Are
Contact Us
Editorial Team
Sitemap
Policy
Privacy Policy
Advertising Policy
Editorial Policy
Corrections Policy
Medical Disclaimer
Alliance
wmo.com
sleep.net
pharm.net
doctors.net
worldsleep.com